All Posts By

Smartkarma Daily Briefs

Daily Brief Health Care: Celltrion Inc, Amgen Inc, GRAIL, Biomarin Pharmaceutical, BioNTech , Baxter International, Davita Healthcare Partners, Zoetis Inc, Illumina Inc and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Merger Between Celltrion Inc and Celltrion Pharm Is Cancelled
  • Amgen Inc.: Expansion of MariTide and Pipeline Advancement! – Major Drivers
  • GRAIL: Focus on MCED Tests, New Restructuring Plan and Solid 2Q Print With +43% Y/Y Revenue Growth
  • BioMarin Pharmaceutical Inc.: Enhanced Geographic Focus and Streamlined Operations for Roctavian Driving Our Optimism! – Major Drivers
  • BioNTech SE: Expansion of MRNA Technology Applications & Major Drivers
  • Baxter International Inc.: An Insight Into The Market Share and Competitiveness in Kidney Care! – Major Drivers
  • DaVita Inc.: A Bear’s Perspective! – Major Drivers
  • Zoetis Inc.: Enhanced Direct-to-Consumer Marketing and ROI Focus Driving Our Optimism! – Major Drivers
  • Illumina Inc.: The Tale Of Global Market Penetration and Expansion! – Major Drivers


Merger Between Celltrion Inc and Celltrion Pharm Is Cancelled

By Douglas Kim

  • Celltrion Inc announced that its proposed merger with Celltrion Pharm has been cancelled due to disapproval of this deal among an overwhelming percentage of Celltrion Inc shareholders.
  • This cancellation of a merger between Celltrion Inc and Celltrion Pharm is likely to continue to have a positive impact on Celltrion Inc and negative impact on Celltrion Pharm.
  • The major reason is because Celltrion Pharm trades at high valuation multiples while Celltrion Inc trades at lower valuation multiples. Celltrion Pharm’s P/B valuation is more than 3x Celltrion Inc’s.

Amgen Inc.: Expansion of MariTide and Pipeline Advancement! – Major Drivers

By Baptista Research

  • Amgen’s second quarter 2024 financial results signify a substantial 20% year-over-year increase reaching $8.4 billion in revenue, representing a robust period for the company.
  • Notably, this is credited to a widespread growth across multiple product lines, with particular strength observed in medicines like Repatha, EVENITY, BLINCYTO, TEZSPIRE, and others in the inflammation and oncology sectors.
  • Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

GRAIL: Focus on MCED Tests, New Restructuring Plan and Solid 2Q Print With +43% Y/Y Revenue Growth

By Andrei Zakharov

  • GRAIL, a commercial-stage healthcare company and maker of MCED blood test called Galleri, reported its quarterly results for the first time as independent publicly traded company.
  • The 2Q print was solid, with +43% y/y revenue growth, ~35,200 Galleri tests sold and ~$32M total revenue all better than expected.
  • Finally, management expects moderate revenue growth rates in 2025 and subsequent years due to cost reductions and decreasing investment in other programs beyond Galleri.

BioMarin Pharmaceutical Inc.: Enhanced Geographic Focus and Streamlined Operations for Roctavian Driving Our Optimism! – Major Drivers

By Baptista Research

  • BioMarin Pharmaceutical Inc. reported a strong performance in its second quarter of 2024 earnings, achieving several milestones while continuing to refine its strategic priorities to enhance profitability and drive sustainable growth.
  • Beginning with the financial performance, BioMarin announced a 20% year-over-year growth in total revenues, reaching $712 million for the quarter.
  • This growth was notably driven by the robust demand for Voxzogo, which itself experienced a substantial 62% revenue increase to $184 million.

BioNTech SE: Expansion of MRNA Technology Applications & Major Drivers

By Baptista Research

  • BioNTech’s second quarter of 2024 earnings revealed a company navigating both ongoing strides in its primary COVID-19 vaccine franchise and advancing its footprint in the oncology sector.
  • The call demonstrated BioNTech’s commitment to expanding its product offerings while managing the shifts in market demands and regulatory landscapes.
  • For the second quarter of 2024, the total revenue reported by BioNTech was approximately EUR 129 million, a decline from EUR 168 million in the same quarter the previous year.

Baxter International Inc.: An Insight Into The Market Share and Competitiveness in Kidney Care! – Major Drivers

By Baptista Research

  • Baxter International Inc. presented its second quarter 2024 earnings, displaying significant progress stemming from its strategic overhaul and operational enhancements.
  • The results surpassed the expected guidance in both revenue and earnings per share (EPS), prompting an uplifting revision in the full-year financial forecast.
  • This positive outcome is indicative of the successful implementation of operational efficiencies and a centralized business model that is beginning to bear fruit.

DaVita Inc.: A Bear’s Perspective! – Major Drivers

By Baptista Research

  • DaVita reported another robust quarter in Q2 2024, demonstrating solid performance metrics that underline the company’s ongoing efforts to enhance its services and fiscal management.
  • Under the leadership of CEO Javier Rodriguez, DaVita has maintained a positive growth trajectory, albeit with some hurdles that were also highlighted during the earnings call.
  • This analysis includes critical insights gathered from the earnings discussions, focusing on both the positive outcomes and areas posing challenges for the company.

Zoetis Inc.: Enhanced Direct-to-Consumer Marketing and ROI Focus Driving Our Optimism! – Major Drivers

By Baptista Research

  • Zoetis reported strong financial results in the second quarter of 2024, showcasing a robust operational growth across various segments and products.
  • Revenue increased by 11% operationally, while adjusted net income saw a significant operational growth of 18%.
  • The well-balanced growth was evident with a 12% increase in the U.S. and a 10% operational rise internationally, demonstrating the company’s effective market strategies and innovative product offerings.

Illumina Inc.: The Tale Of Global Market Penetration and Expansion! – Major Drivers

By Baptista Research

  • In the second quarter of 2024, Illumina posted revenue results that exceeded expectations.
  • While the revenue from core Illumina stood at $1.1 billion, demonstrating solid execution against strategic priorities, the company admits facing challenges due to extended sales cycles and concerns over global economic pressures which affected equipment orders.
  • Despite these hurdles, consumption of sequencing activity consumables saw a significant rise primarily driven by the NovaSeq X Plus, emphasizing an ongoing transition that spells potential future growth.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: Woori Financial Group , S&P/ASX 200, Yuexiu Real Estate Investment Trust, Vista Land & Lifescapes and more

By | Daily Briefs, Financials

In today’s briefing:

  • Value-Up Flow Trading Opportunities Arising from NPS’s 10% Ownership Ceiling on Banks
  • EQD | The ASX200 Can Rally Higher (If This Is A Rally…)
  • Morning Views Asia: Lenovo, Citicore Renewable Energy, Vedanta Resources
  • Vista Land & Lifescapes – Earnings Flash – H1 FY 2024 Results – Lucror Analytics
  • Morning Views Asia: Lenovo, Citicore Renewable Energy, Vedanta Resources


Value-Up Flow Trading Opportunities Arising from NPS’s 10% Ownership Ceiling on Banks

By Sanghyun Park

  • NPS is concerned that aggressive value-up measures by bank holding companies and ongoing cancellations might quickly use up their room up to the 10% ownership limit.
  • With their stake already at mid-8%, they may not buy as much as the index suggests, creating new trading opportunities in the four major bank holding companies.
  • Woori Financial has more room for buying, so as the year ends, NPS’s skewed-buying could give it a better price impact than other bank holding companies.

EQD | The ASX200 Can Rally Higher (If This Is A Rally…)

By Nico Rosti

  • The S&P/ASX 200 has been quietly rallying since its (modest) -11% correction in 2023, mostly unaffected by global turmoils, even the latest sell-off in US, Asia and Europe was “non-damaging”.
  • The index has already recovered a large part of the losses suffered for only 1 week, very brief if we consider that the SPX INDEX had corrected for 4 weeks.
  • Now that the S&P/ASX 200 has rallied strongly we want to analyze its pattern model, to identify the area where it could pull back again (or slow down).

Morning Views Asia: Lenovo, Citicore Renewable Energy, Vedanta Resources

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Vista Land & Lifescapes – Earnings Flash – H1 FY 2024 Results – Lucror Analytics

By Leonard Law, CFA

Vista Land & Lifescapes’ (VLL) H1/24 results were acceptable, with improved earnings and margin expansion. That said, cash flows stayed negative and debt continued to rise. Hence, leverage remained moderately weak.

VLL maintains a sizeable portfolio of securities investment and investment properties, which generate recurring income and support the balance sheet. The investments could also be monetised if needed, albeit their market value is unclear. We expect the company’s liquidity needs to be manageable, given VLL’s reasonable access to funding.


Morning Views Asia: Lenovo, Citicore Renewable Energy, Vedanta Resources

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Alibaba Group Holding , ASM Pacific Technology, China Traditional Chinese Medicine, Midea Group Co Ltd A, Sun Corp, Woori Financial Group , JD.com Inc (ADR), Celltrion Inc and more

By | Daily Briefs, Most Read

In today’s briefing:

  • Alibaba (9988 HK/BABA) Dual Primary Listing: Are We There Yet?
  • HSCEI/HSTECH/HSIII Index Rebalance Preview: Potential Changes, Flow & Positioning
  • To Tender Or Not – Gauging The Future of Sun Corp (6736)
  • TCM (570 HK): A Spoonful Of Sugar …
  • China Traditional Chinese Medicine (570 HK): Relief as Update Favours the Bulls
  • Midea Group (000333 CH): Index Implications at US$3bn Issue Size
  • Sun Corp (6736) – The Future Is Bright
  • Value-Up Flow Trading Opportunities Arising from NPS’s 10% Ownership Ceiling on Banks
  • JD.com (JD US):  Strong Profitability And Upsized Share Buyback in 2Q24
  • Merger Between Celltrion Inc and Celltrion Pharm Is Cancelled


Alibaba (9988 HK/BABA) Dual Primary Listing: Are We There Yet?

By Brian Freitas

  • In its last update, Alibaba Group announced that the company was preparing for its primary listing in Hong Kong and the process was expected to complete by the end August.
  • The Board meets on 14 August to approve results for the three months ending June. Could there be an announcement on the dual primary listing too?
  • Mainland Chinese own between 3.5%-15.5% of companies that converted from Secondary to Dual-Primary in the last few years. Similar buying in Alibaba could take the stock higher from here. 

HSCEI/HSTECH/HSIII Index Rebalance Preview: Potential Changes, Flow & Positioning

By Brian Freitas


To Tender Or Not – Gauging The Future of Sun Corp (6736)

By Travis Lundy

  • The revised/final True Wind Tender Offer for up to 19% of Sun Corp (6736 JP) ends this week. With the “excitement” the last two weeks, the SunCorp/CLBT ratio is higher.
  • The minimum threshold is relatively low. The Tender will most likely succeed with very high pro-ration. 
  • For those on the edge, I discuss possibilities on the back end. It will be less liquid, but that may not be bad.

TCM (570 HK): A Spoonful Of Sugar …

By David Blennerhassett

  • A 14.8% gain month-to-date, including this past Monday’s 6.5% pop – you just knew something positive was taking place behind closed doors. And leaking its way into the public.   
  • So it was no real surprise to read in the latest monthly update announcement on the HKEx that various regulatory approvals are almost, but not quite, satisfied.
  • The wording in the announcement strikes a positive tone. Even remaining conservative on the timeline, this could be wrapped up before year-end. 

China Traditional Chinese Medicine (570 HK): Relief as Update Favours the Bulls

By Arun George

  • China Traditional Chinese Medicine (570 HK)’s monthly update reinforces the bull case. The gross spread has remained uncomfortably high since falling on no news on 26 June. 
  • The monthly update will relieve the bulls, as the consortium has finally made the regulatory submissions. The update stresses that the filing delay is due to an unwieldy consortium. 
  • Potential stumbling blocks remain, which should not be an issue. Nevertheless, the risk (17.7% downside to the undisturbed price)/reward (21.4% gross spread) remains attractive. 

Midea Group (000333 CH): Index Implications at US$3bn Issue Size

By Brian Freitas

  • Midea Group Co Ltd A (000333 CH) has got approval to list on the HKEX (388 HK) and reports are that the listing could be up to US$3bn.
  • That issue size is around half of the maximum that the company can issue. But it would still need cornerstone investors and a nice discount on the H-shares.
  • The stock will still get included in some indices even with the scaled down size, and inclusion in Southbound Stock Connect is a given.

Sun Corp (6736) – The Future Is Bright

By Travis Lundy

  • The reason why Sun Corp (6736 JP) has traditionally traded at a large discount to its potential outcome is the possibility of inefficient or delayed value realisation. 
  • Materially ALL of the value of the company is in its holding in Cellebrite DI (CLBT US). True Wind Capital, the SPAC sponsor of CLBT, just bought 19% of SunCorp. 
  • They bought that for the CLBT, or the value realisation thereof. And now with the slightly surprising Tender Offer result, the chances of a better outcome are now higher.

Value-Up Flow Trading Opportunities Arising from NPS’s 10% Ownership Ceiling on Banks

By Sanghyun Park

  • NPS is concerned that aggressive value-up measures by bank holding companies and ongoing cancellations might quickly use up their room up to the 10% ownership limit.
  • With their stake already at mid-8%, they may not buy as much as the index suggests, creating new trading opportunities in the four major bank holding companies.
  • Woori Financial has more room for buying, so as the year ends, NPS’s skewed-buying could give it a better price impact than other bank holding companies.

JD.com (JD US):  Strong Profitability And Upsized Share Buyback in 2Q24

By Steve Zhou, CFA

  • Profitability of the business surprised on the upside, as the net profit margin of JD.com increased from 3% in 2Q23 to 5% in 2Q24.
  • Share buyback accelerated in 2Q24, as the company bought USD2.1bn worth of stock in the quarter, up from USD1.2bn in 1Q24. 
  • The stock is trading at 7x 2024 PE, with a yield of >10% through dividend and buyback.

Merger Between Celltrion Inc and Celltrion Pharm Is Cancelled

By Douglas Kim

  • Celltrion Inc announced that its proposed merger with Celltrion Pharm has been cancelled due to disapproval of this deal among an overwhelming percentage of Celltrion Inc shareholders.
  • This cancellation of a merger between Celltrion Inc and Celltrion Pharm is likely to continue to have a positive impact on Celltrion Inc and negative impact on Celltrion Pharm.
  • The major reason is because Celltrion Pharm trades at high valuation multiples while Celltrion Inc trades at lower valuation multiples. Celltrion Pharm’s P/B valuation is more than 3x Celltrion Inc’s.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief Consumer: Sun Corp, Alibaba Group Holding , JD.com Inc (ADR), Ola Electric, Cainiao Smart Logistics Network, Prataap Snacks Ltd, Coupang , Nike, Dentsu Inc and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Sun Corp (6736) – The Future Is Bright
  • Alibaba (BABA US): Strategy at Work
  • JD.com (JD US):  Strong Profitability And Upsized Share Buyback in 2Q24
  • Ola Electric: Takes Aim at India Motorcycle Mass Market with Competitive Pricing
  • CaiNiao Q1FY Results: Most Interesting Read-Through Is Dramatic Slowdown in X-Border Activity
  • Prataap Snacks: Market Expansion, Challenges, and Future Plans
  • Coupang Inc.: Market Expansion Through WOW Membership Program Is A Critical Growth Lever!
  • Nike Inc’s Downslide Reversed? Bill Ackman’s Pershing Square Thinks So! – Here’s Why! (8/24)
  • Ola Electric (OLAELEC): EV Maker Receives Turbo Boost from Lock-Up Expiries for Index Inclusion
  • Dentsu Group – Positive momentum


Sun Corp (6736) – The Future Is Bright

By Travis Lundy

  • The reason why Sun Corp (6736 JP) has traditionally traded at a large discount to its potential outcome is the possibility of inefficient or delayed value realisation. 
  • Materially ALL of the value of the company is in its holding in Cellebrite DI (CLBT US). True Wind Capital, the SPAC sponsor of CLBT, just bought 19% of SunCorp. 
  • They bought that for the CLBT, or the value realisation thereof. And now with the slightly surprising Tender Offer result, the chances of a better outcome are now higher.

Alibaba (BABA US): Strategy at Work

By Eric Chen

  • Mixed June quarter results at first glance suggest corporate overhaul strategy is working, with clear evidence Taobao/Tmall is stabilizing in terms of market share and profitability.
  • Better platform monetization and clear timetable for achieving break-even by non-e-commerce business segments mean double-digit earnings CAGR by FY26 in our view.
  • We expect Alibaba’s upswing business cycle and moderating headwind of housing market slump are paving the way for the stock’s re-rating in the next 12-24 months. 

JD.com (JD US):  Strong Profitability And Upsized Share Buyback in 2Q24

By Steve Zhou, CFA

  • Profitability of the business surprised on the upside, as the net profit margin of JD.com increased from 3% in 2Q23 to 5% in 2Q24.
  • Share buyback accelerated in 2Q24, as the company bought USD2.1bn worth of stock in the quarter, up from USD1.2bn in 1Q24. 
  • The stock is trading at 7x 2024 PE, with a yield of >10% through dividend and buyback.

Ola Electric: Takes Aim at India Motorcycle Mass Market with Competitive Pricing

By Devi Subhakesan

  • Ola Electric (OLAELEC IN)  launched its highly anticipated electric motorcycles, offering models from mass market to super premium.
  • With entry-level e-bikes priced to compete directly with Hero Motocorp (HMCL IN)’s popular models, Ola could disrupt India’s high-volume, competitive motorcycle market.
  • Ola’s ebike volumes could ramp up quickly if its performance meets expectations of the value conscious customer base in the mass-end of the market.

CaiNiao Q1FY Results: Most Interesting Read-Through Is Dramatic Slowdown in X-Border Activity

By Daniel Hellberg

  • Alibaba logistics arm CaiNiao’s revenue growth slowed in the June quarter
  • Our main takeaway is that Chinese X-border eComm continues to slow
  • We believe all of the large X-border eComm platforms may be affected

Prataap Snacks: Market Expansion, Challenges, and Future Plans

By Sudarshan Bhandari

  • Prataap Snacks Ltd (DIAMOND IN)‘s acquisition of Avadh Snacks and recent manufacturing expansions, including new facilities in Kolkata, Jammu, and Rajkot, align with its growth strategy.
  • PSL reported an 8.7% revenue increase in Q1 FY25, despite facing raw material cost inflation and rising overheads. The company has streamlined distribution and cost management to sustain margins.
  • PSL’s focus on expanding high-margin segments and leveraging cost efficiencies positions it as a resilient and cheapest player in the snack industry.

Coupang Inc.: Market Expansion Through WOW Membership Program Is A Critical Growth Lever!

By Baptista Research

  • Coupang’s recent quarter highlights a strong performance driven by strategic initiatives and operational improvements, alongside a promising outlook tempered by certain challenges that need to be addressed for sustained growth.
  • The company’s revenue grew by 30% year-over-year in constant currency, showcasing impressive sales momentum.
  • This growth was partly fueled by the acquisition of Farfetch, which played a key role in the company’s multifaceted growth strategy.

Nike Inc’s Downslide Reversed? Bill Ackman’s Pershing Square Thinks So! – Here’s Why! (8/24)

By Baptista Research

  • Nike Inc has long been a dominant player in the global sportswear industry, renowned for its innovation and strong brand presence.
  • However, recent challenges, including macroeconomic headwinds and market dynamics, have led to a downslide in its stock performance.
  • Enter Pershing Square Capital Management, led by billionaire investor Bill Ackman, which recently disclosed a $229 million stake in Nike.

Ola Electric (OLAELEC): EV Maker Receives Turbo Boost from Lock-Up Expiries for Index Inclusion

By Dimitris Ioannidis

  • Ola Electric (OLAELEC IN) is likely to get added at the March 2025 review following the lock-up expiry in November 2024 which increases the fcap way above the fcap threshold.
  • Current fcap for February 2025 review is ~$1.2bn following the lock-up expiry in November 2024. Inclusion is based on whether fcap passes the prevailing fcap threshold.
  • The lock-up expiry in February 2025, increases the probability of addition in May 2025 review if it fails inclusion in February. 

Dentsu Group – Positive momentum

By Edison Investment Research

Dentsu’s H124 figures show sequential quarterly improvements, with the group posting organic growth of 0.2% in Q2. Encouragingly, this is in part ascribed to improved pitch win rates in all four reporting regions, underpinning growth projections through H224 and into FY25, despite the persistent difficult macroeconomic backdrop. The One dentsu initiative is driving collaborative efforts across group capabilities and geographies and we expect this to be at the heart of the new medium-term strategy, to be unveiled in H2. In the meantime, the Business transformation (BX) offering is proving effective in Japan and is now to be rolled out more widely. The shares continue to be valued well below peers and we would expect this discount to narrow with improving operational performance.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Quantitative Analysis: ASX Short Interest Weekly (Aug 9th): CSL and more

By | Daily Briefs, Quantitative Analysis

In today’s briefing:

  • ASX Short Interest Weekly (Aug 9th): CSL, Qbe Insurance, Macquarie, Agl Energy, Telstra


ASX Short Interest Weekly (Aug 9th): CSL, Qbe Insurance, Macquarie, Agl Energy, Telstra

By Ke Yan, CFA, FRM

  • We analyzed the changes in short interest of ASX Stocks as of Aug 9th (reported today) which has an aggregated short interest worth USD20.6bn.
  • We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases & decreases in short value, short as multiple of ADT.
  • We highlight short interest changes in CSL, Qbe Insurance, Macquarie, Agl Energy, Telstra.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ESG: Huhtamaki – ESG Report – Lucror Analytics and more

By | Daily Briefs, ESG

In today’s briefing:

  • Huhtamaki – ESG Report – Lucror Analytics
  • Will Mandatory Reporting of the Ratio Alone Lead to Higher Ratio of Women in Managerial Positions?


Huhtamaki – ESG Report – Lucror Analytics

By Leonard Law, CFA

Lucror Analytics’ ESG Scores are based on a 3-tiered scale and are adjusted for Controversies (if applicable).
We assess Huhtamaki’s ESG as “Strong”, in line with its Governance score, while the company’s Environmental and Social pillars are “Adequate”. Controversies are “Immaterial” and Disclosure is “Strong”. 


Will Mandatory Reporting of the Ratio Alone Lead to Higher Ratio of Women in Managerial Positions?

By Aki Matsumoto

  • The government’s goal of “30% women in management positions by 2030” should be included by a bill to be submitted to the ordinary Diet session in 2025.
  • The bill should include specific measures to provide government support to companies that created environment in which women can give birth and raise children without having to leave their jobs.
  • Not only is the value of the goods and services from the women’s perspective overlooked, as well as the underutilization of human resources from about half of the universes.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): Japan Morning Connection: Sanken Electric and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • Japan Morning Connection: Sanken Electric, Nidec, Asahi Intecc
  • [Blue Lotus Daily]:ATAT US/TCOM US/BEKE US/NIO US/LI US/1810 HK/1211 HK/XPEV US/LKNCY US
  • [Blue Lotus Daily-TMT Update]:700 HK/BILI US/BABA US/PDD US/JD/3690HK/ZTO/1519HK/2352 CH/SHEIN/TCOM
  • Earnings: ALGM, LRCX, TOLEY, NVMI, ONTO


Japan Morning Connection: Sanken Electric, Nidec, Asahi Intecc

By Andrew Jackson

  • Tech laggards bought in the US showing many in the market scrambling to catch the upside after the rapid snapback from last weeks drop.
  • Server related strength after Cisco numbers may see sentiment for Nidec finally improving with its cooling modules business emerging as an earnings driver.
  • Strong numbers for Coherent confirm the positive trends for its optical transceiver business which points to continued upside for AI data center plays

[Blue Lotus Daily]:ATAT US/TCOM US/BEKE US/NIO US/LI US/1810 HK/1211 HK/XPEV US/LKNCY US

By Eric Wen

  • ATAT US/TCOM US:Daily Traffic Volume growth on highways is flattish YoY During the Summer Travel Season(-/-)
  • BEKE US: Decrease in New Short-term Loans to Residents in July, but Increase in New Long-term Loans(+)
  • BEKE US:House prices continued to decline in July . (-)

[Blue Lotus Daily-TMT Update]:700 HK/BILI US/BABA US/PDD US/JD/3690HK/ZTO/1519HK/2352 CH/SHEIN/TCOM

By Ying Pan

  • 700 HK: Based on <DnF Mobile> Developer Nexon’s 2Q24 Financial Report, the Game Generated around RMB 7bn in Revenue During the Quarter (+)
  • 700 HK: <League of Legends> to Introduce Another PVE Game Mode (+)
  • BILI US: Bilibili’s <Aether Gazer> to Shut Down on November 12 (/)

Earnings: ALGM, LRCX, TOLEY, NVMI, ONTO

By Douglas O’Laughlin

  • Some more minor data points and highlights: KLIC (ball bonders) says that utilization is 75-80%, which is a good read on China despite the negative industrial headwind.
  • Allegro Microsystems is definitely scraping the bottom, and while Sanken (its distributor) is still increasing its inventory, I like the setup there.
  • Arrow Electronics (Distributor) says things are improving, which is a big counterpoint to everything else.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: ACME Solar Holdings – Strong Sector Tailwinds but Need to Keep an Eye on Profitability and more

By | Daily Briefs, ECM

In today’s briefing:

  • ACME Solar Holdings – Strong Sector Tailwinds but Need to Keep an Eye on Profitability
  • Jiangsu Zenergy Battery Technologies Pre-IPO Tearsheet


ACME Solar Holdings – Strong Sector Tailwinds but Need to Keep an Eye on Profitability

By Ethan Aw

  • ACME Solar Holdings (1700918D IN) is looking to raise US$360m in its upcoming India IPO. 
  • ACME Solar (ACME) is a renewable energy firm with a portfolio of solar, wind, hybrid and firm and dispatchable renewable energy (FDRE) projects.
  • In this note, we talk about the company’s historical performance.

Jiangsu Zenergy Battery Technologies Pre-IPO Tearsheet

By Ethan Aw

  • Jiangsu Zenergy Battery Technologies (JSZENERGY CH) is looking to raise up to US$300m in its upcoming HK IPO. The deal will be run by CICC, and CMB International.
  • Jiangsu Zenergy Battery Technologies (Zenergy from hereon) is an EV and energy storage system (ESS) battery manufacturer in China. 
  • It provides integrated battery solutions, encompassing battery cells, modules, packs, racks, and battery management systems dedicated to large-scale applications of electrochemical products to interconnect omni-scenarios of land, sea and air.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Event-Driven: China Traditional Chinese Medicine (570 HK): Relief as Update Favours the Bulls and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • China Traditional Chinese Medicine (570 HK): Relief as Update Favours the Bulls
  • Examining the September Reshuffle of the KOSPI Size Index Series
  • TCM (570 HK): A Spoonful Of Sugar …
  • Midea Group (000333 CH): Index Implications at US$3bn Issue Size
  • Namoi Cotton (NAM AU): Louis Dreyfus Has This Stitched Up
  • Hankook Tire & Technology: M&A of Hanon System Falling Apart?
  • Porsche Automobile Holding: H1, Model Update, Discount to NAV


China Traditional Chinese Medicine (570 HK): Relief as Update Favours the Bulls

By Arun George

  • China Traditional Chinese Medicine (570 HK)’s monthly update reinforces the bull case. The gross spread has remained uncomfortably high since falling on no news on 26 June. 
  • The monthly update will relieve the bulls, as the consortium has finally made the regulatory submissions. The update stresses that the filing delay is due to an unwieldy consortium. 
  • Potential stumbling blocks remain, which should not be an issue. Nevertheless, the risk (17.7% downside to the undisturbed price)/reward (21.4% gross spread) remains attractive. 

Examining the September Reshuffle of the KOSPI Size Index Series

By Sanghyun Park

  • The September KOSPI Size Index rebalancing could bring back the typical price impacts seen over the past decade, unlike the March rebalancing.
  • The previous rebalancing had anomalies due to newly listed stocks in LARGE and a stronger downward trend in LARGE-to-MID transitions, disrupting the expected price impact.
  • For September’s rebalancing, fewer distortions are expected compared to March. The NPS Mid to Small Cap fund, a key influence, shows no significant changes in benchmark or AUM.

TCM (570 HK): A Spoonful Of Sugar …

By David Blennerhassett

  • A 14.8% gain month-to-date, including this past Monday’s 6.5% pop – you just knew something positive was taking place behind closed doors. And leaking its way into the public.   
  • So it was no real surprise to read in the latest monthly update announcement on the HKEx that various regulatory approvals are almost, but not quite, satisfied.
  • The wording in the announcement strikes a positive tone. Even remaining conservative on the timeline, this could be wrapped up before year-end. 

Midea Group (000333 CH): Index Implications at US$3bn Issue Size

By Brian Freitas

  • Midea Group Co Ltd A (000333 CH) has got approval to list on the HKEX (388 HK) and reports are that the listing could be up to US$3bn.
  • That issue size is around half of the maximum that the company can issue. But it would still need cornerstone investors and a nice discount on the H-shares.
  • The stock will still get included in some indices even with the scaled down size, and inclusion in Southbound Stock Connect is a given.

Namoi Cotton (NAM AU): Louis Dreyfus Has This Stitched Up

By David Blennerhassett

  • Since Louis Dreyfus Company (LDC) first announced a A$0.51/share Offer, by way of a Scheme, on the 28 November 2023, and Olam Agri countered, there have been significant developments. 
  • Both suitors have now tabled off-market Offers (A$0.67/share from LDC, and A$0.70/share from Olam Agri). Both Offers are open for tendering. Both have extended their closing dates numerous times.
  • And both suitors have also faced ACCC scrutiny. As of today, only LDC, currently holding a 20.2% stake in Namoi, is in the clear.

Hankook Tire & Technology: M&A of Hanon System Falling Apart?

By Douglas Kim

  • There are increasing signs that Hankook Tire & Technology’s M&A of Hanon Systems could be falling apart. 
  • The deadline for signing the main M&A contract to purchase a 25% stake in Hanon Systems has been postponed indefinitely.
  • New contingent liabilities at Hanon Systems have been uncovered during the 10 week due diligence process of Hanon Systems by Hankook T&T.

Porsche Automobile Holding: H1, Model Update, Discount to NAV

By Jesus Rodriguez Aguilar

  • Porsche SE is trading at a 35.3% discount to NAV, vs. 32.4% long-term average, implying a 68% probability that Porsche SE will be liable for c. €6.5 billion legal claims.
  • I think this is too harsh. Shares are trading at a Fwd P/E of 2.5x and a dividend yield of 7.8%, which I consider very attractive. 
  • Porsche SE presents an attractive opportunity to gain exposure to Volkswagen and Porsche AG. Porsche SE is focusing on deleveraging which should drive a reduction in the discount.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Credit: Yanlord Land – Earnings Flash – H1 FY 2024 Results – Lucror Analytics and more

By | Credit, Daily Briefs

In today’s briefing:

  • Yanlord Land – Earnings Flash – H1 FY 2024 Results – Lucror Analytics


Yanlord Land – Earnings Flash – H1 FY 2024 Results – Lucror Analytics

By Leonard Law, CFA

Yanlord Land’s H1/24 results were acceptable in our view. The company reported robust top-line growth, albeit margins weakened amid the difficult operating environment. Positively, Yanlord continued to reduce debt and maintain stable leverage. In addition, the company has successfully refinanced its borrowings using cheaper onshore secured debt, which has helped to improve interest costs.

That said, Yanlord’s headroom to raise future secured debt has been reduced, as the bulk of its investment properties has already been pledged. Still, the company might be able to upsize its existing secured loans with higher LTV, or issue loans backed against new assets. Meanwhile, Yanlord continues to face sales pressure and a shrinking land bank in the absence of new land acquisitions.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars